NOC — Northrop Grumman Corporation

Near-term sentiment is bullish: the 2026-10-20 Q3 print beat consensus EPS (~$7.18-$7.20 vs. $7.89), FY26 MTM-adjusted EPS guidance was raised to $29.35-$29.75, and book-to-bill was 1.5x with backlog at $109.6B. The stock rose 4.8% that day and 11.4% over the prior week, though it remained 9.6% below its 200-day SMA and down 12.25% over six months, so this is a rebound in sentiment rather than a full trend reversal.

Revenue growth has reaccelerated from a 2025 soft patch: Q3 2026 revenue of $11.12B rose 6.7% y/y after +5.1% in Q2 and +4.4% in Q1, versus a -6.6% y/y Q1 2025 and only +1.3% in Q2 2025. Operating margin remains choppy around program charges - Q3 2026 was 11.4% vs. 11.9% y/y, better than Q4 2025's 8.9% and Q1 2025's 6.1% but below Q2 2025's 13.8% - while gross margin was stable at ~21.2%. EPS has grown but not smoothly: Q3 2026 EPS of $7.89 vs. $7.67 y/y, Q2 $7.68 vs. $8.15, and Q1 $6.14 vs. $3.32 on an easy charge-affected comparison; TTM EPS is $31.81. FCF is highly seasonal (Q1 2026 -$1.82B, Q4 2025 +$3.24B) but improving, with Q3 2026 FCF $1.44B vs. $1.26B y/y. Net: growth is accelerating and backlog visibility is strong; margins remain the swing factor, not a structural collapse.

Fair, not cheap. As of 2026-10-20, trailing P/E was 16.85 vs. its 5-year average of 19.34, and P/S was 1.744 vs. 1.90, which looks modestly discounted. But on next-FY EPS of $28.93 the stock trades at ~18.5x, and on FY26 guidance midpoint of $29.55 it is ~18.1x - close to its historical average - while PEG is 1.2 and the 1.77% yield is unexceptional. The trailing P/E discount is flattered by $31.81 TTM EPS; forward earnings do not show a clear bargain.

The market has now paid for the Q3 beat: at $535.18, NOC is around 18x FY26 EPS guidance and ~18.5x next-FY consensus, versus analyst consensus target of $595.69 (~20x FY26). The +4.8% report-day move says expectations were low after a 12.25% six-month decline, but the raised guide and record backlog are largely reflected at this price. Further upside needs either a multiple re-rating toward 19-20x or additional EPS beats; a stall back toward the $510 previous close would show the market treating 18x as fair.

As of 2026-10-20, RSI(14) was 63.42 - strong but not overbought - and the stock was 8.18% above its 20-day SMA and 2.32% above its 50-day SMA, yet still 9.64% below its 200-day SMA. The one-week gain of 11.4% signals a sharp post-earnings rebound, but the six-month return of -12.25% and price below the 200-day mean the longer trend is not repaired. Entry-timing implication: chasing after an 11% week is risky; better risk/reward on a pullback toward the 50-day/previous close area or on a confirmed close above the 200-day.

• U.S. defense budget appropriations and authorization: funding delays, continuing resolutions, or sequestration can slow awards and revenue conversion even with a $109.6B backlog.
• Geopolitical demand: elevated global threats and allied modernization are supporting record orders and multi-year visibility for programs like B-21, Sentinel, and classified space.
• Inflation, labor, and supply chain: fixed-price development contracts remain exposed to cost overruns and skilled-labor shortages, which can compress segment margins.
• Interest rates and pension accounting: rate moves affect pension discount rates and MTM adjustments, adding earnings volatility outside core operations.
• Defense sector policy/rotation: shifting budget priorities (e.g., space, nuclear deterrence vs. legacy aviation) and political scrutiny can change program funding trajectories.

• B-21 Raider flight-test and production milestones; positive progress supports the Aeronautics growth story and backlog conversion.
• Sentinel ICBM development/budget progression; funding clarity or schedule updates could ease fixed-price overrun concerns - or worsen them.
• Defense appropriations and authorization legislation in Washington, including fiscal 2027 priorities for deterrence and space.
• Q4 2026 earnings (estimated 2027-01-28) and FY27 guidance; watch book-to-bill, margin execution, and FCF conversion.
• Record $109.6B backlog conversion; quarterly book-to-bill above 1.0x would reinforce the reacceleration thesis.

• Fixed-price development contract cost overruns, especially Sentinel, B-21, and classified programs, could force charges and margin compression.
• Defense budget delays, continuing resolutions, or shifting priorities could slow awards and cash conversion despite the backlog.
• Supply chain and skilled-labor inflation may pressure margins on long-duration contracts.
• Program concentration and classified revenue limit visibility; a single schedule or cost setback can move sentiment.
• Valuation risk: at ~18x forward EPS, there is limited cushion if growth decelerates or margins disappoint.
• Pension/MTM and interest-rate volatility can distort GAAP earnings and guidance comparisons.

Northrop is a high-quality defense prime with improving revenue, record $109.6B backlog, and better FCF, but the 2026-10-20 price of $535.18 already reflects much of that: ~18x FY26 guidance is fair, not cheap, and the stock is still below its 200-day SMA after a sharp one-week rally. I would call risk/reward balanced - long-term holders can justify owning the backlog visibility and 1.77% yield, but new money should wait for a pullback or clearer budget/program catalysts rather than chase the post-earnings pop.

I applied 18.7x to a forward EPS base of $29.55, the FY26 MTM-adjusted guidance midpoint - a slight discount to the 19.34 five-year average P/E but above the 16.85 trailing P/E because forward EPS is lower than TTM - yielding about $552.59. A cross-check at roughly 12x EV/EBITDA on forward EBITDA also points to the mid-$500s.